Drug intelligence / Profile preview

Thy1 single-chain variable fragment

Development stage
Preclinical
Modality
scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

**Thy1 single-chain variable fragment (Thy1-scFv)** is a recombinant antibody fragment that specifically targets the thymocyte differentiation antigen 1 (Thy1/CD90), a cell-surface glycoprotein overexpressed in the neovasculature of various cancers, notably pancreatic ductal adenocarcinoma (PDAC)[1]. This molecule is engineered as a single-chain variable fragment (scFv), combining the variable regions of the heavy and light chains of an antibody into a single polypeptide via a flexible linker. Thy1-scFv retains high binding specificity to Thy1, enabling its use in molecular imaging for early cancer diagnosis, particularly for PDAC, where over 80% of cases show Thy1 upregulation in tumor vasculature[1][2][4]. It is typically produced via recombinant expression in *E. coli*, and it can be conjugated to imaging agents, such as ultrasound contrast microbubbles, to enable targeted detection of tumors in vivo[1].

Other names
Thy1-scFvThy-1-scFvThy 1-scFv
02

Targets

THY1 (CD90)

Beyond the preview

Go deeper on Thy1 single-chain variable fragment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thy1 single-chain variable fragment.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call